New menopause drug elinzanetant calmed hot flushes and improved sleep

Vasomotor symptoms, the hot flushes many women experience around menopause, can be frequent and intense enough to erode quality of life and sleep. Not every woman can or wants to use existing treatments, so new options are under active study. Elinzanetant is one such drug, and individual trials had tested it against placebo. This analysis pooled those trials to give a clearer read on whether it works and whether it is safe.

The authors systematically searched PubMed, Embase and Cochrane databases for randomised trials comparing elinzanetant with placebo in women with menopause-related vasomotor symptoms. Three trials qualified, reporting on 995 patients, of whom 551 received elinzanetant, with mean ages between 54.4 and 55.6 years. Results were pooled as mean differences and risk ratios. The pre-specified outcomes were the frequency and intensity of vasomotor symptoms, quality of life, and sleep disturbance.

Elinzanetant significantly reduced how often vasomotor symptoms occurred and how intense they were compared with placebo. Quality of life improved on the Menopause-Specific Quality of Life Questionnaire, and sleep improved on a patient-reported sleep disturbance scale. Importantly, adverse events were no more common with the drug than with placebo. On the symptom frequency and sleep outcomes, the trials agreed with each other closely, which strengthens confidence in the direction of the effect.

Pooling three consistent trials moves elinzanetant from a promising single-trial story towards a more established one, at least over the timescales those trials covered. It does not answer everything: three trials is still a modest base, the analysis says nothing about how the drug compares with other menopause treatments, and long-term safety sits outside its reach. Larger and longer experience will determine where it lands in practice.

If hot flushes and disturbed sleep are part of your menopause, this is worth knowing as a marker of where treatment research is heading: a drug that eased symptoms, improved sleep and quality of life, and produced side effects at placebo-like rates across pooled trials. It is information for a conversation with a clinician rather than something to act on alone. The honest framing is encouraging pooled evidence, not a finished story.